



Wednesday, 8 October 2025 | research report

NEUCA: buy (new)

NEU PW; NEU.WA | Healthcare, Poland

Healthy Core, Trials Turning the Corner

We initiate coverage on NEUCA, Poland's leading pharmaceutical distributor, which is also expanding its footprint in the clinical contract research organization (CRO) segment, with a 'Buy' recommendation and a Target Price of PLN 869.

Year-to-date, NEUCA's share price has been down 21% due to weak 1H25 results. However, we expect earnings momentum to improve starting in 3Q25, with 2026E EBITDA projected to rebound by 17% y/y to PLN 467m, which is 3% above consensus. This implies an EV/EBITDA multiple of 9x, which we view as undemanding given the long-term prospects in Clinical Trials.

Healthy Core: Stable Trends in Distribution, Growth in Manufacturing

The Polish pharmacy market has been growing at a CAGR of approximately 10% in recent years, and this pace was sustained through the first eight months of 2025, with the second half of September also showing strong momentum. We expect NEUCA's Distribution segment to continue benefiting from this market growth, while the Manufacturing segment should maintain robust performance, supported by ongoing medicalization and the launch of new OTC products.

Headwinds in Clinical Trials, But The Worst Is Over...

The Clinical Trials segment reported an EBITDA loss in 1H25, driven by project cancellations at Kapadi (CRO) and margin pressure. However, the backlog improved to PLN 1.2bn (+18% y/y), and Pratia (clinical site management) delivered double-digit growth. Management expects positive EBIT in 2H25, supported by a gradual recovery in the CRO business. M&A activity may serve as a catalyst, with due diligence currently underway.

... And There Is Good Outlook for Insurance and Medical Operator

The Medical Operator and Insurance segments continue to scale, supported by network expansion and the introduction of new products. The integration of medical and insurance services under a coordinated care model is contributing to margin improvement. We expect both segments to deliver double-digit revenue growth alongside rising profitability.

Earnings Momentum Set to Improve from 3Q25

Following a weak 2Q25, with EBITDA down 19% y/y to PLN 75m, we forecast sequential improvement beginning in 3Q25, supported by normalized marketing costs in Manufacturing, stable Wholesale margins, and positive operating leverage in Clinical Trials. For FY 2025E, we expect EBITDA of PLN 400m (+1% y/y), broadly in line with consensus, and a stronger 2026E at PLN 467m (+17% y/y, 3% above consensus), driven by recovery in Clinical Trials and continued growth across core segments.

Undemanding Multiples

Based on our forecasts, NEUCA is trading at 2025E and 2026E EV/EBITDA multiples of 10.2x and 8.6x, respectively—representing a 17% and 25% discount to its drug distribution peers. We believe this discount is unwarranted given the company's exposure to the Clinical Trials segment.

Our DCF-based 12-month target price is PLN 869, implying an upside potential of 29%.

current price*
target price
mCap
free float
ADTV (3M)
*Price as of October 07, 2025, 5:00 PM

PLN 676.00 PLN 869.00 PLN 3,100.5m PLN 1,162.7m PLN 0.8m


Shareholder structure

Kazimierz Herba	26.89%
Wiesława Teresa Herba	24.54%
Tadeusz Wesołowski	10.35%
Others	38.70%

About NEUCA

NEUCA is No 1 distributor of pharmaceuticals in Poland, manufacturer of Rx and OTC drugs. The company also owns outpatient medical care clinics, has been developing a clinical CRO business via M&As and offers health insurance services.

NEU share price vs. WIG Index



Company	Target Price		Recommendation	
	New	Old	New	Old
NEUCA	869.00	-	buy	-
Company	Current Price		Target Price	Upside
NEUCA	676.00		869.00	+29%

(PLN m)	2023	2024	2025E	2026E	2027E
Revenues	11,813	12,612	13,358	14,105	14,738
Norm. EBITDA	363	395	400	467	544
Norm. Net income	130	155	157	207	270
Net Income	146	154	157	207	270
P/E (x)	23.7	19.6	19.8	15.3	11.7
EV/EBITDA (x)	10.3	10.3	10.2	8.6	7.2
Dividend yield	2.0%	2.3%	2.4%	2.7%	3.1%

Source: NEUCA, mBank, E - mBank estimates

Beata Szparaga-Waśniewska, CFA Head of Equity Research Equity Analyst, Expert +48 510 929 021 beata.szparaga-wasniewska@mbank.pl



List of abbreviations and ratios used by mBank:

List of abbreviations and ratios used by mBank:

EW (Enterprise Value) – Equity Value + Net Debt; EBIT – Earnings Before Interest and Taxes; EBITDA – EBIT + Depreciation & Amortisation; Net Debt – Borrowings + Debt Securities + Interest-Bearing Loans – Cash and Cash Equivalents; P/E (Price/Earnings) – Price Per Share Divided by Earnings + Depreciation & Amortisation; P/B (Price to Book Value) – Price Per Share Divided by Book Value Per Share; P/CF (Price to Cash Flow) – Price Divided by Cash Flow from Operations; ROE (Return on Equity) – Earnings Divided by Shareholders' Equity; ROCE (Return on Capital Employed) – EBIT x (Average Assets – Current Liabilities); ROCE (Return on Interest + Net Debt); FCFF (Free Cash Flow to Firm) – Cash Flow from Operations - CAPEX - Lease Payments; FCFE (Free Cash Flow to Equity) – Free Cash Flow to Firm - Net Interest Expense (incl. Debt + Leases); EBITDA margin – EBITDA/Sales

OVERWEIGHT (OW) – a rating which indicates that we expect a stock to outperform the broad market **NEUTRAL (N)** – a rating which indicates that we expect the stock to perform in line with the broad market **UNDERWEIGHT (UW)** – a rating which indicates that we expect the stock to underperform the broad market

Recommendations of Biuro maklerskie mBanku:

A recommendation is valid for a period of 12 months, unless a subsequent recommendation is issued in this period. Expected returns from individual recommendations are as follows:

BUY – we expect that the rate of return from an investment will be at least 10%

HOLD – we expect that the rate of return from an investment will range from 0% to +10%

SELL - we expect that an investment will bear a loss

The foregoing principle maybe waived where circumstances warrant, including but not limited to periods of increased share price volatility experienced by the company that is the subject of a recommendation immediately preceding the time the recommendation is issued. Recommendations are updated at least once every twelve months.

mBank S.A. with its registered office in Warsaw at Prosta 18 renders brokerage services via a dedicated organisational unit, the Brokerage Bureau, which uses the Polish name Biuro maklerskie mBanku.

mBank S.A. as part of the Exchange's Analytical Coverage Support Programme ("Programme", https://www.gpw.pl/eacsp) prepares analytical reports for Auto Partner S.A, Cyber_Folks S.A, Newag S.A. These documents are prepared at the request of Gielda Papierów Wartościowych w Warszawie S.A. ("WSE"), which is entitled to copyrights to these materials. mBank S.A. receives remuneration from the WSE for the preparation of the reports. All documents prepared for the Programme are available at:
https://www.mdm.pl/ui-pub/site/market_and_analysis/analysis_and_recommendations/analytical_coverage_support_programme

This document has been created and published by Biuro maklerskie mBanku. This report expresses the knowledge as well as opinions of the authors on day the report was prepared. The opinions and estimates contained herein constitute our best judgment at this date and time, and are subject to change without notice. This report was prepared with due care and attention, observing principles of methodological correctness and objectivity, on the basis of sources available to the public, which Biuro maklerskie mBanku considers reliable, including information published by issuers, shares of which tare subject to recommendations. However, Biuro maklerskie mBanku, in no case, guarantees the accuracy and completeness of the report, in particular should sources on the basis of which the report was prepared prove to be inaccurate, incomplete or not fully consistent with the facts. mBank S.A. bears no responsibility for investment decisions taken on the basis of this report or for any damages incurred as a result of investment decisions taken on the basis of this report.

This document does not constitute an offer or invitation to subscribe for or purchase any financial instruments and neither this document nor anything contained herein shall form the basis of any contract or commitment whatsoever. It is being furnished to you solely for your information and may not be reproduced or redistributed to any other person This document does not constitute investment, legal, accounting or other advice, and mBank is not liable for damages resulting from or related to the use of data provided in the documents. This document may not be copied, duplicated and/or be directly or indirectly distributed in the United States, Canada, Australia or Japan, nor transferred to citizens or residents of a state where its distribution may be legally restricted, which does not limit the possibility of publishing materials prepared for the Programme on Auto Partner S.A, Cyber_Folks S.A, Newag S.A, mBank or WSE websites. Persons who disseminate this document should be aware of the need to comply

Recommendations are based on essential data from the entire history of a company being the subject of a recommendation, with particular emphasis on the period since the previous recommendation

Investing in shares is connected with a number of risks including, but not limited to, the macroeconomic situation of the country, changes in legal regulations as well as changes on commodity markets. Full elimination of these risks is virtually impossible

It is possible that mBank S.A. in its brokerage activity renders, will render or in the past has rendered services for companies and other entities mentioned in this report.

BM, as a separate organisational unit of the Bank, may buy or sell (or may have bought or sold in the past) the financial instruments discussed herein in the name and on behalf of clients subject to powers of attorney granted by the clients

mTFI may hold (or may have held in the past) positions in the financial instruments discussed herein, or in related instruments, held in the investment portfolios of funds operated or managed by mTFI The Bank may hold (or may have held in the past) positions in the financial instruments discussed herein, or in related instruments, held in the trading portfolios or banking portfolios managed by the Bank. The Bank and other members of the Bank's group of companies may hold (or may have held in the past) positions in the financial instruments discussed herein, or in related instruments, held in portfolios

mBank S.A. does not rule out offering brokerage services to an issuer of securities being the subject of a recommendation.

Biuro Maklerskie mBanku S.A. ("BM") has put in place internal regulations governing the active management of conflicts of interest, which establish internal organizational and administrative frameworks and information barrier protocols to prevent and avoid conflicts of interest in connection with recommendations. Different types of brokerage activities are separated from each other within BM's internal organizational structure, including the equity research department, which is separated from other brokerage activities. Information barriers, called "Chinese walls," have been created to restrict the exchange of information between different organizational units and employees of BM.

Information concerning a conflict of interest arising in connection with issuing a recommendation (should such a conflict exist) is located below

The present report was not transferred to the issuer prior to its publication.

The Issuer is a client of Biuro maklerskie mBanku.

The Issuer is a client of mBank S.A.
The Issuer is a counterparty to mBank S.A.

The production of this recommendation was completed on October 8, 2025, 7:57 AM.

This recommendation was first disseminated on October 8, 2025, 8:25 AM

This document is an extract from a recommendation produced by Biuro maklerskie mBanku.

mBank S.A., its shareholders and employees may hold long or short positions in the issuer's shares or other financial instruments related to the issuer's shares

Copying or publishing this report, in full or in part, or disseminating in any way information contained in this report requires the prior written consent of mBank S.A.

Recommendations are addressed to all Clients of Biuro maklerskie mBanku.

All investment recommendations and strategies issued by mBank S.A. over the last 12 months are available at: https://mdm.pl/bm/analizy

The activity of mBank S.A. is subject to the supervision of the Polish Financial Supervision Commission

Individuals who did not participate in the preparation of recommendations, but had or could have had access to recommendations prior to their publication, are employees of Biuro maklerskie mBanku authorised to access the premises in which recommendations are prepared and/or individuals having to access to recommendations based on their corporate roles, other than the analysts mentioned as the authors of this recommendations.

This publication constitutes investment research in the meaning of Art. 36.1 of Commission Delegated Regulation (EU) 2017/565.

The compensation of the research analysts responsible for preparing investment research is determined independently of and without regard to the compensation of or revenue generated by any other employee of the Bank, including but not limited to any employee whose business interests may reasonably be considered to conflict with the interests of the persons to whom the investment research prepared by the Research Department of Biuro maklerskie mBanku is disseminated. With that being said, since one of the factors taken into consideration when determining the compensation of research analysts is the degree of fulfillment of annual financial targets by customer service functions, there is a risk that the adequacy of compensation offered to persons preparing investment research will be questioned by a competent oversight body.

For U.S. persons only: This research report is a product of mBank SA which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of FINRA or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution by mBank SA only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a (6)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors, mBank SA has entered into an agreement with a U.S. registered broker-dealer, Cabrera Capital Markets. ("Cabrera"). Transactions in securities discussed in this research report should be effected through Cabrera or another U.S. registered broker dealer.

Strong and weak points of valuation methods used in recommendations:

DCF – acknowledged as the most methodologically correct method of valuation; it consists in discounting financial flows generated by a company; its weak point is the significant susceptibility to a change of forecast assumptions in the model.

Relative – based on a comparison of valuation multipliers of companies from a given sector; simple in construction, reflects the current state of the market better than DCF; weak points include substantial

variability (fluctuations together with market indices) as well as difficulty in the selection of the group of comparable companies.

Economic profits - discounting of future economic profits; the weak point is high sensitivity to changes in the assumptions made in the valuation model.

Discounted Dividends (DDM) – discounting of future dividends; the weak point is high sensitivity to changes in the assumptions as to future dividends made in the valuation model.

NAV - valuation based on equity value, one of the most frequently used method in case of developing companies; the weak point of the method is that it does not factor in future changes in revenue/profits

mBank did not issue any recommendations for NEUCA in the 12 months prior to this publication

mBank S.A.

Prosta 18 00-850 Warszawa http://www.mbank.pl/

Research Department

Beata Szparaga-Waśniewska, CFA director +48 510 929 021 beata.szparaga-wasniewska@mbank.pl biotechnology, healthcare

Michał Konarski +48 515 025 640 michal.konarski@mbank.pl banks, financials

Janusz Pięta +48 506 065 659 janusz.pieta@mbank.pl retail, e-commerce Mateusz Krupa, CFA deputy director +48 571 608 973 mateusz.krupa@mbank.pl strategy

Mikołaj Lemańczyk, CFA +48 501 663 511 mikolaj.lemanczyk@mbank.pl banks, financials, property developers

Jakub Sargsyan +48 519 419 895 marlen.sargsyan@mbank.pl industrials, mining Paweł Szpigiel +48 509 603 258 pawel.szpigiel@mbank.pl media, IT, telco, e-commerce

Piotr Poniatowski +48 509 603 046 piotr.poniatowski@mbank.pl gaming, leisure

Sales and Trading

Traders

Piotr Gawron director +48 698 832 853 | +48 22 697 48 95 piotr.gawron@mbank.pl

Andrzej Kowalczyk +48 789 868 634 | +48 22 697 47 44 andrzej.kowalczyk@mbank.pl

Andrzej Sychowski +48 605 848 003 | +48 22 697 48 46 andrzej.sychowski@mbank.pl

Sales, Foreign Markets

Marzena Łempicka-Wilim deputy director +48 696 427 249 marzena.lempicka-wilim@mbank.pl Paweł Cylkowski deputy director +48 503 684 130 | +48 22 697 47 31 pawel.cylkowski@mbank.pl

Karol Kułaj +48 509 602 984 | +48 22 697 49 85 karol.kulaj@mbank.pl

Łukasz Płaska +48 784 449 962 | +48 22 697 47 90 lukasz.plaska@mbank.pl Piotr Brożyna +48 512 756 702 | +48 22 697 48 47 piotr.brozyna@mbank.pl

Patryk Gniadek tel. +48 505 116 638 | +48 22 697 48 82 patryk.gniadek@mbank.pl

Private Client Sales

Maciej Sokołowski director maciej.sokolowski@mbank.pl Jarosław Banasiak deputy director jaroslaw.banasiak@mbank.pl